Procedure
TransCon CNP for Achondroplasia
This trial uses TransCon CNP to help children and adolescents with achondroplasia grow their bones properly. It is for those who have already been part of a previous trial. The treatment continues for an extended period.
Growth Hormone Receptor Agonist
Lonapegsomatropin for Growth Hormone Deficiency
This trial is designed to evaluate the long-term safety and efficacy of a growth hormone deficiency treatment administered once-weekly. The study participants are adults (males and females) who have completed the treatment period in a previous study.
Hormone Therapy
Growth Hormone Replacement for Gulf War Illness
This trial is testing if giving synthetic growth hormone to veterans with Gulf War Illness and growth hormone deficiency can reduce body fat and improve their symptoms. The study will check if this treatment is safe and effective over several months. If successful, it could lead to better care for these veterans. Growth hormone (GH) treatment has been shown to increase height velocity in children with Prader-Willi syndrome, decrease weight-for-height index values and body fat mass, and have a positive effect on lean body mass during therapy.
Corticosteroid
Tildacerfont for Congenital Adrenal Hyperplasia
This trial is testing a medication called tildacerfont to see if it is safe and effective for people with Congenital Adrenal Hyperplasia (CAH). The treatment involves taking the medication for a period of time, followed by a safety check. Tildacerfont aims to help balance hormones that are not properly regulated in people with CAH. Tildacerfont has been studied for its effectiveness in adults with Congenital Adrenal Hyperplasia.
Popular Filters
Trials for ACH Patients
Tyrosine Kinase Inhibitor
Infigratinib for Achondroplasia
This trial is testing a medicine called infigratinib in children aged 3 to 11 years with Achondroplasia. The medicine works by blocking proteins that cause abnormal bone growth. The children have already participated in an earlier study.
Peptide Hormone Analog
TransCon CNP for Achondroplasia
This trial tests a shot called TransCon CNP in children aged 2 to 10 with Achondroplasia. The shot helps bones grow by delivering a special protein. The goal is to see if it can improve growth in these children. TransCon CNP has shown promising results in increasing growth in children with achondroplasia.
Trials for CAH Patients
Corticosteroid
Crinecerfont for Congenital Adrenal Hyperplasia
This trial is testing a medication called crinecerfont to help children with a hormone disorder called CAH. The study will compare crinecerfont to another treatment over several months. The goal is to see if crinecerfont can safely and effectively balance their hormone levels.
Gene Therapy
Gene Therapy for Congenital Adrenal Hyperplasia
This trial tests a new gene therapy called BBP-631, delivered by a virus through an IV, in adults with classic congenital adrenal hyperplasia. The goal is to see if it is safe and effective over several years. BBP-631 is a gene therapy delivered by a virus, similar to other gene therapies that have shown promise in treating adrenal disorders.
Corticosteroid
Crinecerfont for Congenital Adrenal Hyperplasia
This trial is testing a new medication called crinecerfont in adults with a genetic condition that affects hormone production. The study aims to see if crinecerfont can help balance their hormone levels and improve their symptoms. Participants will take the medication for several months, with an option to continue longer.
Corticosteroid
CRN04894 for Congenital Adrenal Hyperplasia
This trial is testing a new drug called CRN04894 in people with a genetic condition called classic congenital adrenal hyperplasia (CAH). The condition affects hormone production, and current treatments may not work well. The study will see if CRN04894 can safely and effectively help manage hormone levels by targeting the underlying cause of CAH.
Behavioural Intervention
Virtual Education Program for Congenital Adrenal Hyperplasia
This trial tests if online lessons can help young people with CAH learn to manage their health as they transition to adult care. It aims to improve their knowledge, medication adherence, and appointment scheduling.
Corticosteroid
Chronocort for Congenital Adrenal Hyperplasia
This trial is testing Chronocort, a medication for people aged 16 and over with Congenital Adrenal Hyperplasia (CAH). It aims to see if Chronocort can safely and effectively manage their hormone levels. Chronocort works by releasing hormones in a way that mimics the body's natural rhythm. Chronocort is a modified-release formulation of hydrocortisone designed to better mimic the body's natural cortisol circadian rhythm.
Phase 3 Trials
Growth Hormone Replacement Therapy
Somatropin for Growth Hormone Deficiency and Concussion
This trial is testing if giving extra growth hormone can help improve the quality of life for adults who have low growth hormone levels and mild brain injuries. Growth hormone treatment has been shown to improve quality of life in adults with growth hormone deficiency.
Corticosteroid
Crinecerfont for Congenital Adrenal Hyperplasia
This trial is testing a medication called crinecerfont to help children with a hormone disorder called CAH. The study will compare crinecerfont to another treatment over several months. The goal is to see if crinecerfont can safely and effectively balance their hormone levels.
Corticosteroid
Crinecerfont for Congenital Adrenal Hyperplasia
This trial is testing a new medication called crinecerfont in adults with a genetic condition that affects hormone production. The study aims to see if crinecerfont can help balance their hormone levels and improve their symptoms. Participants will take the medication for several months, with an option to continue longer.
Trials With No Placebo
Gene Therapy
Gene Therapy for Congenital Adrenal Hyperplasia
This trial tests a new gene therapy called BBP-631, delivered by a virus through an IV, in adults with classic congenital adrenal hyperplasia. The goal is to see if it is safe and effective over several years. BBP-631 is a gene therapy delivered by a virus, similar to other gene therapies that have shown promise in treating adrenal disorders.
Tyrosine Kinase Inhibitor
Infigratinib for Achondroplasia
This trial is testing a medicine called infigratinib in children aged 3 to 11 years with Achondroplasia. The medicine works by blocking proteins that cause abnormal bone growth. The children have already participated in an earlier study.
View More Related Trials
Frequently Asked Questions
Introduction to
What are the top hospitals conducting undefined research?
In the realm of medical research, there are countless conditions that still puzzle healthcare professionals and researchers alike. These hospitals listed here have stepped up to tackle one such condition, currently labeled as "undefined." The National Institutes of Health Clinical Center in Bethesda leads the charge with four ongoing clinical trials dedicated to understanding this enigmatic condition. Despite its mysterious nature, it is important to note that there have been no previous trials conducted on undefined at these institutions or any other hospital for that matter.
Baylor College of Medicine in Houston also joins the quest by actively engaging in four clinical trials aimed at unraveling the mysteries surrounding undefined. Similarly, Ascendis Pharma Investigational Sites located in both Madison and Houston contribute their efforts through three active trials each, striving to shed light on this perplexing condition.
Lastly, Vanderbilt University Medical Center adds its expertise from Nashville into the mix with three ongoing undefined trials. It is a reminder that despite having zero previously recorded studies on this specific condition across all five hospitals mentioned above - these esteemed medical centers stand ready and committed to exploring uncharted territories within medicine.
While we may not yet fully comprehend what defines "undefined," it is through endeavors like these clinical trials where exciting discoveries can be made. With each new step taken towards unlocking its secrets, we inch closer to providing answers and solutions for individuals affected by this elusive health concern.
Which are the best cities for undefined clinical trials?
In the realm of undefined clinical trials, several cities stand out as leaders in research and development. Seattle, Washington takes the lead with 11 active trials investigating treatments such as Crinecerfont, Lonapegsomatropin, and Somatropin. Bethesda, Maryland follows closely behind with 9 ongoing studies focused on innovative approaches like Chronocort, Flutamide, and AAV BBP-631. Houston and Dallas in Texas both have 7 active trials each exploring various treatments including BMN 111, TransCon CNP, Abiraterone acetate among others. Los Angeles in California also shows promise with 6 active trials examining potential breakthroughs like Crinecerfont and AAV BBP-631. These cities serve as hubs for cutting-edge clinical research that paves the way for advancements in medical care.
Which are the top treatments for undefined being explored in clinical trials?
Currently, there are several top treatments being explored in clinical trials for undefined. These include:
- Daratumumab: 6 active trials, first listed in 2012
- Belantamab mafodotin: 4 active trials, first listed in 2018
- Lenalidomide: 3 active trials, first listed in 2003
These treatments show promise and have garnered significant attention as researchers strive to find effective solutions for undefined.
What are the most recent clinical trials for undefined?
The field of clinical trials is constantly evolving, and recent studies have shed light on potential breakthroughs for undefined conditions. One such trial investigated the efficacy of LUM-201 at a dosage of 1.6 mg/kg/day, aiming to provide relief for patients with undefined disorders. Another study explored the benefits of sequential dosing as a treatment approach for this enigmatic condition. Additionally, TransCon CNP showed promise in both Phase 2 and Phase 3 trials, offering hope for improved outcomes in individuals facing undefined health challenges. Furthermore, BMN 111 injection with an injector pen emerged as a potential therapeutic option during its Phase 1 trial period. As researchers continue their quest to unravel the mysteries surrounding these unknown conditions, optimism grows regarding finding effective treatments that can bring relief to those affected by them.
What undefined clinical trials were recently completed?
Apologies, but as an AI language model, I don't have access to current data on clinical trials or the ability to browse the internet. My responses are based on general knowledge up until September 2021. To find information about recently completed clinical trials, I recommend checking reputable sources such as clinicaltrials.gov or consulting with medical professionals and researchers in the field. They can provide accurate and up-to-date information regarding specific clinical trials that have been recently completed.